A haploidentical stem cell transplant is an advanced form of allogeneic hematopoietic stem cell transplantation (transplantation using cells from a donor) where the donor shares exactly half of the patient's human leukocyte antigen (HLA) tissue type. The primary clinical goal is to eradicate malignant or malfunctioning bone marrow cells through high-dose conditioning therapy and rebuild a healthy blood and immune system. The newly infused donor stem cells generate fresh red blood cells, white blood cells, and platelets while creating a donor-derived immune system capable of attacking remaining cancer cells through a process known as the graft-versus-leukemia effect.

The procedure begins with donor stem cell collection using apheresis (for peripheral blood stem cells) or bone marrow harvesting under general anesthesia. The patient undergoes a conditioning regimen consisting of high-dose chemotherapy (such as fludarabine, busulfan, or cyclophosphamide) and optional total body irradiation over 5 to 7 days. On Day 0, donor stem cells are infused through a central venous catheter in a process similar to a blood transfusion. On Days +3 and +4 post-transplant, high-dose cyclophosphamide is administered intravenously to eliminate alloreactive donor T-cells. Additional immunosuppressive medications, such as tacrolimus and mycophenolate mofetil, are started on Day +5. Patient monitoring continues in a positive-pressure HEPA-filtered hospital room until neutrophil engraftment is established.

Clinical evidence demonstrates several key clinical benefits of haploidentical stem cell transplantation:

• Universal Donor Availability: Over 95 percent of patients have an immediately accessible haploidentical donor within their biological family, eliminating long search delays (EBMT 2023 guidelines).
• Immediate Donor Access: Family donors are readily available for urgent collection, reducing the risk of disease progression during donor search phases.
• Robust Graft-versus-Leukemia Effect: Natural killer cell mismatched haplotypes can enhance immunologic clearance of residual leukemic cells (Ruggeri et al., 2002).
• Comparable Survival Outcomes: Long-term disease-free survival rates for haploidentical transplants using post-transplant cyclophosphamide are comparable to matched unrelated donor transplants in acute leukemia (CIBMTR 2021 cohort data).
• Future Donor Cell Access: Family donors remain easily accessible if subsequent donor lymphocyte infusions or additional stem cell boosts are required.

Recovery from a haploidentical stem cell transplant occurs in distinct clinical phases. Early recovery occurs during the first 30 days inpatient, during which neutrophil engraftment typically occurs between day 14 and day 21. Intermediate recovery spans days 30 to 100 post-transplant, focusing on platelet recovery, immune reconstitution, and outpatient surveillance for graft-versus-host disease and opportunistic viral infections. Full immune system recovery requires 12 to 24 months, during which patients receive prophylactic anti-infective medications and undergo re-vaccination with standard childhood and adult vaccines.

Haploidentical stem cell transplantation is indicated for severe hematologic conditions requiring stem cell replacement when a fully matched donor is unavailable. Key indications include:

• Acute myeloid leukemia (AML)
• Acute lymphoblastic leukemia (ALL)
• Myelodysplastic syndromes (MDS)
• Chronic myeloid leukemia (CML) in advanced or resistant phases
• Severe aplastic anemia and bone marrow failure syndromes
• High-grade non-Hodgkin lymphoma and Hodgkin lymphoma
• Primary myelofibrosis
• Inherited metabolic disorders and severe immune deficiencies

Pre-treatment evaluation includes organ function testing (echocardiogram, pulmonary function testing, comprehensive metabolic panel, serum creatinine), infectious disease screening (CMV, EBV, HIV, Hepatitis B and C), bone marrow biopsy to confirm disease status, and high-resolution HLA typing of patient and candidate donors. Patient preparation involves surgical placement of a tunneled central venous catheter (Hickman line), dental clearance to eliminate infection sources, nutritional optimization, psychosocial evaluation, and fertility preservation counseling where appropriate.

Common and mild risks include nausea, mucositis (mouth sores), temporary hair loss, fatigue, and low blood cell counts requiring transfusions. Moderate to severe complications include acute graft-versus-host disease (affecting skin, gut, or liver), chronic graft-versus-host disease, primary or secondary graft failure, cytomegalovirus (CMV) reactivation, invasive fungal infections, sinusoidal obstruction syndrome (hepatic veno-occlusive disease), hemorrhagic cystitis, and idiopathic pneumonia syndrome. Long-term risks include secondary malignancies, endocrine dysfunction, infertility, and cataracts.

The patient journey begins with an extensive pre-transplant workup lasting two to four weeks, evaluating heart, lung, liver, and kidney function alongside donor HLA typing. Once a half-matched donor is cleared, the patient is admitted to an isolation unit for conditioning therapy, which lasts five to seven days and consists of chemotherapy with or without radiation. On day zero, the donor stem cells are infused intravenously. The patient stays in a protective isolation room for three to five weeks during the engraftment phase, receiving supportive care, transfusions, and post-transplant immunosuppression. Following engraftment, outpatient monitoring continues for 100 days to manage potential complications, followed by long-term follow-up care over several years.